Rare Biomarkers Specimen Collection And Stabilization Market Report 2026

Rare Biomarkers Specimen Collection And Stabilization Market Overview

• Rare Biomarkers Specimen Collection And Stabilization market size has reached to $35.29 billion in 2025 • Expected to grow to $55.35 billion in 2030 at a compound annual growth rate (CAGR) of 9.2% • Growth Driver: Increasing Prevalence Of Cancer Is Driving The Growth Of The Rare Bio Markers Specimen Collection And Stabilization • Market Trend: Innovative Automated Pre-Analytical Platforms Revolutionize Rare Biomarker Specimen Collection And Stabilization • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rare Biomarkers Specimen Collection And Stabilization Market?

Rare biomarkers specimen collection and stabilization refers to the process of collecting and preserving biological samples containing rare or low-abundance molecules that serve as indications of specific biological processes, diseases, or situations. These biomarkers could be specific proteins, nucleic acids, metabolites, or other substances. The aim of collecting and preserving rare biomarkers is to enable accurate and reliable measurement and analysis of these molecules for diagnostic, prognostic, and therapeutic applications. The main types of rare biomarker specimen collection and stabilization are circulating cell-free DNA (ccFDNA), circulating tumor cells (CTCs), exosomes, or extracellular vesicles. Circulating cell-free DNA (CCFDNA) includes DNA fragments that are freely circulating in the bloodstream and can originate from both healthy and diseased cells. These fragments carry genetic information and can be analyzed for various diagnostic purposes, such as detecting cancer or monitoring treatment effectiveness. It uses various specimens, such as serum or plasma and others for several applications including non-invasive prenatal testing (NIPT), oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases, and others. These are used by various end-users, such as hospitals, perinatal clinics, public health labs, private or commercial labs, physician labs, research institutes, and others.

What Is The Rare Biomarkers Specimen Collection And Stabilization Market Growth Forecast?

The rare biomarkers specimen collection and stabilization market size is expected to see strong growth in the next few years. It will grow to $55.35 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing adoption of precision diagnostics, rising demand for early disease detection, expansion of genomic and transcriptomic testing, growing investments in biomarker-driven drug development, increasing integration of ai in biomarker analysis. Major trends in the forecast period include increasing adoption of liquid biopsy collection techniques, growing use of advanced stabilization reagents, rising demand for high-sensitivity biomarker preservation, expansion of non-invasive diagnostic applications, enhanced focus on sample integrity and traceability.

Global Rare Biomarkers Specimen Collection And Stabilization Market Segmentation

1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles 2) By Specimen: Serum Or Plasma, Other Specimens 3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications 4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users Subsegments: 1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA 2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow 3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum

What Is The Driver Of The Rare Biomarkers Specimen Collection And Stabilization Market?

The increasing prevalence of cancer is expected to propel the growth of the rare biomarker specimen collection and stabilization market going forward. Cancer refers to a broad group of diseases characterized by the uncontrolled growth and spread of abnormal cells. The rise in cancer prevalence is driven by factors such as environmental exposures, lifestyle risks including smoking and poor diet, and genetic susceptibility, all of which contribute to a growing need for precise diagnostic and monitoring tools. Rare biomarker specimen collection and stabilization play a critical role in enabling the accurate preservation of blood- and tissue-based biomarkers used for early detection, molecular profiling, and therapy selection in oncology. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, over 35 million new cancer cases were projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the rare biomarker specimen collection and stabilization market.

Key Players In The Global Rare Biomarkers Specimen Collection And Stabilization Market

Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

Global Rare Biomarkers Specimen Collection And Stabilization Market Trends and Insights

Major companies operating in the rare biomarkers specimen collection and stabilization market are focusing on developing advanced solutions, such as automated plasma and cell sample preparation, to preserve biomarker integrity and enable high-throughput multiomics. Automated pre-analytical platforms refer to technologies that standardize the processing of blood samples such as plasma separation, cell fixation, and slide preparation at the point of collection, ensuring consistent specimen quality without manual handling or specialized tubes. For instance, in April 2024, Tethis S.p.A., an Italy-based biotechnology company, announced the enrollment of the first two patients in a clinical study of its See.d platform, which automates standardized plasma and cell sample preparation for multiomic liquid biopsy, including fixation of rare circulating tumor and immune cells on nanocoated SmartBioSurface slides. Designed to maximize sample integrity and facilitate seamless analysis of cell-free DNA and circulating tumor cells from a single draw, the platform supports the end-to-end workflow of rare biomarker specimen collection and stabilization.

What Are Latest Mergers And Acquisitions In The Rare Biomarkers Specimen Collection And Stabilization Market?

In June 2025, Foresight Diagnostics, a US-based diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, partnered with QIAGEN to develop and commercialize a kit based version of Foresight’s CLARITY assay. Through this collaboration, the companies aim to transform a highly sensitive minimal residual disease (MRD) liquid biopsy test based on circulating tumor DNA (ctDNA) into a regulated in vitro diagnostic (IVD) and companion diagnostic (CDx) kit for lymphoma and other hematological cancers. QIAGEN is a Germany-based manufacturer and supplier of products for the rare biomarkers specimen collection and stabilization.

Regional Outlook

North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Rare Biomarkers Specimen Collection And Stabilization Market?

The rare biomarkers specimen collection and stabilization market consists of revenues earned by entities by providing services such as sample collection, stabilization and preservation, customized collection protocols, bio banking and storage and data management and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare biomarkers specimen collection and stabilization market also includes sales of biomarker collection kits, laboratory equipment, training and educational materials, quality control materials, and sample storage containers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rare Biomarkers Specimen Collection And Stabilization Market Report 2026?

The rare biomarkers specimen collection and stabilization market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rare biomarkers specimen collection and stabilization industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.